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Abstract
Objective:	To	describe	the	effect	of	maternal	vaccination	on	birth	outcomes	in	rural	
Nepal,	modified	by	timing	of	vaccination	in	pregnancy	and	influenza	virus	activity.
Methods:	A	secondary	analysis	was	conducted	using	data	from	two	annual	cohorts	of	
a	randomized	controlled	trial.	A	total	of	3693	pregnant	women	from	Sarlahi	District	
were	enrolled	between	April	25,	2011,	and	September	9,	2013.	All	participants	were	
aged	15–40	years	and	received	a	trivalent	 inactivated	 influenza	vaccine	or	placebo.	
The	 outcome	measures	 included	 birth	 weight,	 pregnancy	 length,	 low	 birth	 weight	
(<2500	g),	preterm	birth,	and	small-	for-	gestational-	age	birth.
Results:	Data	were	available	on	birth	weight	for	2741	births	and	on	pregnancy	length	
for	3623	births.	Maternal	vaccination	increased	mean	birthweight	by	42	g	(95%	confi-
dence	 interval	 [CI]	8–76).	The	magnitude	of	this	 increase	varied	by	season	but	was	
greatest	among	pregnancies	with	high	influenza	virus	circulation	during	the	third	tri-
mester.	Birth	weight	 increased	by	111	g	 (95%	CI	−51	 to	273)	when	75%–100%	of	
a	pregnancy’s	third	trimester	had	high	influenza	virus	circulation	versus	38	g	(95%	CI	
−6	 to	 81)	when	0%–25%	of	 a	 pregnancy’s	 third	 trimester	 had	 high	 influenza	 virus	
	circulation.	However,	these	results	were	nonsignificant.
Conclusion:	 Seasonal	 maternal	 influenza	 vaccination	 in	 rural	 Nepal	 increased	 birth	
weight;	the	magnitude	appeared	larger	during	periods	of	high	influenza	virus	circulation.
ClinicalTrials.gov: NCT01034254.
K E Y W O R D S
Influenza;	Low	birth	weight;	Nepal;	Pregnancy;	Preterm;	Small	for	gestational	age;	Vaccination
1  | INTRODUCTION
In	 2010,	 influenza	 infection	 accounted	 for	 19	200	000	 disability-	
adjusted	 life	 years	worldwide.1	 Pregnant	women	 are	 at	 particularly	
high	 risk	 of	 complications	 from	 influenza	 infection.2	 WHO	 recom-
mends	vaccination	for	pregnant	women.3
One	 study	 showed	 markedly	 increased	 innate	 and	 adaptive	
immune	responses	to	the	influenza	vaccine	when	comparing	pregnant	
with	 non-	pregnant	women,4	 suggesting	 that	 these	 responses	might	
underpin	increased	rates	of	morbidity	and	mortality	among	pregnant	
women.	 Furthermore,	 worse	 health	 outcomes	 resulting	 from	 influ-
enza	infection	has	been	reported	during	late	stages	of	pregnancy	than	
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited. 
©	2017	The	Authors.	International Journal of Gynecology & Obstetrics	published	by	John	Wiley	&	Sons	Ltd	on	behalf	of	International	Federation	of	Gynecology	and	
Obstetrics
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during	early	stages.5	Maternal	influenza	infection	has	also	been	linked	
with	fetal	growth	restriction,	preterm	delivery,	and	fetal	loss.6
Neonates	 born	 growth	 restricted	 and/or	 preterm	 are	 likely	 to	
experience	 both	 immediate	 and	 long-	term	 health	 consequences.	
Those	born	small-	for-	gestational-	age	(SGA)—a	proxy	for	fetal	growth	
restriction—experience	increased	risk	of	neonatal	and	infant	mortality,	
stunted	growth,	and	chronic	disease	in	adulthood.7,8	Likewise,	those	
born	preterm	have	increased	risk	of	neonatal	and	infant	mortality,	as	
well	as	cognitive	and	motor	impairments.8,9
Observational	 studies	 and	 randomized	 controlled	 trials	 (RCTs)	
exploring	the	effect	of	maternal	influenza	vaccination	on	rates	of	SGA	
and	 preterm	 delivery	 have	 reported	mixed	 findings.10–15	 The	Nepal	
Mothers’	Gift	Trial	was	an	RCT	of	maternal	influenza	vaccination	with	
two	annual	cohorts	of	pregnant	women	residing	in	a	rural	area	of	this	
country.15,16	The	 primary	 outcomes	were	maternal	 influenza-	like	 ill-
ness,	 infant	 influenza	 infection,	and	 low	birth	weight	 (LBW;	defined	
as	<2500	g).	Inconsistent	results	were	found	between	the	two	annual	
cohorts;	however,	protective	effects	were	reported	in	at	least	one	of	
these	cohorts	for	all	outcomes	assessed.15
The	aim	of	the	present	analysis	was	to	present	further	details	of	
the	effect	of	maternal	influenza	vaccination	on	birth	weight	and	preg-
nancy	length	among	participants	enrolled	in	the	Nepal	Mothers’	Gift	
Trial.	 The	 effect	 of	 maternal	 vaccination	 on	 birth	 outcomes	 and	 its	
modification	by	pregnancy	length	at	which	vaccination	was	given	and	
by	influenza	virus	activity	were	assessed.	These	issues	are	particularly	
important	to	address	in	locations	with	year-	round	influenza	circulation	
to	determine	the	ideal	timing	of	maternal	vaccination.
2  | MATERIALS AND METHODS
A	secondary	analysis	was	performed	using	the	data	from	an	RCT	that	
examined	 the	 efficacy	 of	 influenza	 immunization	 on	 the	 incidence	 of	
respiratory	illness	and	laboratory-	confirmed	influenza	infection	among	
pregnant	women	and	their	neonates,	with	6	months	of	postpartum	fol-
low-	up.15,16	Ethical	approval	was	obtained	for	the	original	study	and	sub-
sequent	analyses	from	the	Institutional	Review	Boards	of	the	Cincinnati	
Children’s	 Medical	 Center	 (Cincinnati,	 OH,	 USA),	 Johns	 Hopkins	
Bloomberg	School	of	Public	Health	(Baltimore,	MD,	USA),	the	Institute	
of	Medicine	at	Tribhuvan	University	(Kathmandu,	Nepal),	and	the	Nepal	
Health	Research	Council	(Kathmandu,	Nepal).	All	participants	provided	
informed	consent	to	the	original	study	and	use	of	data	for	analysis.
Full	details	of	the	original	methods	and	the	results	for	the	primary	
outcomes	have	been	described	elsewhere.15,16	Briefly,	married,	preg-
nant	women	aged	15–40	years	 living	 in	Sarlahi	District,	Nepal,	were	
invited	 to	 participate.	Women	 who	 had	 already	 received	 influenza	
vaccination	that	season,	planned	to	deliver	outside	the	study	area,	or	
had	allergies	to	vaccine	components	(e.g.	egg)	were	excluded.	Eligible	
women	were	enrolled	in	two	separate	but	sequential	annual	cohorts.	
For	 the	 first	 cohort,	 women	 at	 17–34	weeks	 of	 pregnancy	 were	
enrolled	between	April	25,	2011,	and	April	24,	2012,	and	vaccinated	
on	enrollment.	For	the	second	cohort,	women	were	enrolled	between	
April	25,	2012,	and	April	24,	2013;	they	were	then	randomly	assigned	
a	week	between	17	and	34	weeks	of	pregnancy	at	which	they	would	
undergo	vaccination.	Pregnancy	length	was	calculated	from	the	date	
of	the	last	menstrual	period;	recall	of	the	date	was	aided	by	5-	weekly	
population	pregnancy	surveillance	by	the	study	staff.	Women	in	both	
cohorts	 were	 randomly	 allocated	 to	 receive	 a	 trivalent	 inactivated	
influenza	 vaccine	 or	 saline	 placebo	 in	 blocks	 of	 eight,	 stratified	 by	
pregnancy	length	at	vaccination	(17–25	or	26–34	weeks).	The	partic-
ipants	were	masked	to	their	allocation.	Two	different	formulations	of	
the	vaccine	were	used	(second	formulation	used	starting	from	October	
15,	2012).	Details	on	the	vaccines	are	available	in	Appendix	S1.
All	enrolled	women	were	visited	weekly	by	study	staff,	both	during	
and	after	pregnancy	(follow-	up	continued	to	180	days	after	delivery),	
to	collect	data	on	maternal	and	infant	morbidities	for	each	day	in	the	
previous	week.	These	illness	signs	were	all	self-	reported	by	the	women	
or	other	household	members.	 Influenza-	like	 illness	was	defined	as	a	
fever	in	the	presence	of	either	a	cough	or	sore	throat,	based	on	daily	
self-	reported	data	that	was	collected	on	a	weekly	basis.	Nasal	swabs	
were	 taken	 for	 influenza	 testing	 by	 polymerase	 chain	 reaction17 
among	all	women	presenting	with	fever	plus	one	additional	morbidity	
sign	(persistent	cough,	sore	throat,	nasal	congestion,	or	myalgia)	and	
all	infants	with	fever,	cough,	wheezing,	difficulty	in	breathing,	or	otor-
rhea	on	any	of	the	previous	7	days.	Details	of	the	laboratory	tests	are	
available	elsewhere.15
The	participants	were	instructed	to	notify	study	staff	immediately	
after	delivery,	at	which	time	a	staff	member	visited	the	household	to	
collect	data	on	maternal,	fetal,	and	neonatal	status,	as	well	as	morbid-
ities	and	conditions	during	labor	and	delivery.
The	 main	 outcome	 measures	 were	 birth	 weight	 and	 pregnancy	
length	at	delivery,	and	dichotomous	variables	LBW,	preterm	delivery	
(<37	weeks),	and	SGA.	Only	neonatal	weights	taken	within	72	hours	
of	delivery	were	included;	when	weight	was	taken	beyond	72	hours,	
data	 on	 pregnancy	 length	 could	 still	 be	 contributed.	A	 birth	weight	
lower	 than	 the	 10th	 percentile	 of	 the	 sex-	specific	 and	 gestational-	
age-	specific	INTERGROWTH-	21st	birth	weight	standard18	was	used	
to	define	SGA.	Neonates	at	or	above	the	10th	percentile	were	catego-
rized	as	appropriate-	for-	gestational-	age	(AGA).
The	data	were	analyzed	using	Stata	version	13	(StataCorp,	College	
Station,	TX,	USA).	The	distribution	of	birth	weight	and	pregnancy	length	
at	delivery	was	summarized	by	vaccination	group.	The	data	were	also	
stratified	by	the	formulation	of	the	vaccine	the	mother	received.	The	
infants	were	categorized	by	creating	mutually	exclusive	categories	of	
delivery	weight	and	pregnancy	length	as	follows:	term-	AGA-	not	LBW,	
term-	AGA-	LBW,	term-	SGA-	not-	LBW,	term-	SGA-	LBW,	preterm-	AGA-	
not-	LBW,	preterm-	AGA-	LBW,	and	preterm-	SGA	 (Fig.	S1).8	 Infants	 in	
the	preterm-	SGA	group	were	all	LBW.	The	regression	analyses	con-
ducted	are	summarized	in	Table	1.
3  | RESULTS
The	flow	diagrams	for	the	two	annual	cohorts	are	shown	in	Figures	S2	
and	S3.	A	total	of	3693	pregnant	women	were	enrolled;	1846	received	
placebo	and	1847	received	the	influenza	vaccine.	The	17	deliveries	that	
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occurred	within	 2	weeks	 of	 the	mothers	 receiving	 the	 vaccine	 were	
excluded	from	the	present	analysis	on	the	assumption	that	immunologic	
protection	after	vaccination	requires	2	weeks	for	full	effect.	The	num-
ber	of	eligible	live	births	was	1826	in	the	placebo	group	and	1820	in	the	
vaccinated	group.	Birth	weight	was	measured	within	72	hours	of	deliv-
ery	among	1361	(74.5%)	women	in	the	placebo	group	and	1380	(75.8%)	
in	the	vaccination	group.	Furthermore,	1813	(99.3%)	women	in	the	pla-
cebo	group	and	1810	(99.5%)	in	the	vaccination	group	had	a	pregnancy	
length	within	the	predefined	feasibility	range	(24	to	<50	weeks).
Among	the	2741	women	whose	newborns	were	weighed	within	
72	hours	of	delivery,	31	(1.1%)	had	at	least	one	laboratory-	confirmed	
influenza	 episode	 during	 pregnancy	whereas	 2710	 (98.9%)	 did	 not.	
Additionally,	175	(6.4%)	women	experienced	at	least	one	episode	of	
influenza-	like	illness	during	pregnancy,	whereas	2566	(93.6%)	did	not.
Table	 S1	 presents	 birthweight	 stratified	 by	whether	 the	mother	
experienced	 influenza	 or	 influenza-	like	 illness.	 The	 adjusted	 regres-
sion	 results	 showed	 that	 the	 neonates	 of	mothers	with	 laboratory-	
confirmed	influenza	at	any	point	in	pregnancy	were	on	average	55	g	
(95%	 confidence	 interval	 [CI]	 −213	 to	 103)	 lighter	 at	 delivery	 than	
neonates	whose	mothers	did	not	have	 influenza,	but	 the	difference	
was	nonsignificant.	Likewise,	the	neonates	of	mothers	with	influenza-	
like	illness	at	any	point	in	pregnancy	were	significantly	lighter	at	deliv-
ery	than	were	those	of	mothers	who	did	not	experience	influenza-	like	
illness	 (70	g,	 95%	CI	 −139	 to	 −2).	The	 total	 duration	 of	 illness	was	
1–26	days	 (median	 4	days)	 for	 those	with	 influenza	 and	 1–12	days	
(median	3	days)	 for	 those	with	 influenza-	like	 illness.	The	duration	of	
such	illness	was	not	associated	with	birth	weight	(data	not	shown).
The	 birth	 weight	 distribution	 in	 the	 placebo	 and	 vaccination	
groups	 is	presented	 in	Table	2	and	Figure	S4.	Greater	differences	 in	
birth	weight	between	the	placebo	and	vaccination	groups	were	seen	
during	periods	of	more	intensive	A/H1N1	or	B/Yamagata	circulation	
(data	not	shown).
As	 previously	 reported,15	 influenza	 vaccination	 increased	 mean	
birth	weight	by	42	g	 (95%	CI	8–76)	but	had	no	effect	on	pregnancy	
length	(difference	0.07	weeks,	95%	CI	−0.09	to	0.24).	A	statistically	sig-
nificant	reduction	was	found	for	LBW	(adjusted	risk	ratio	0.85,	95%	CI	
0.75–0.97)	but	not	for	SGA	or	preterm	birth.15	The	breakdown	of	neo-
nates	by	SGA,	preterm,	and	LBW	is	shown	in	Table	3.	Compared	with	
the	placebo	group,	 the	vaccinated	group	had	a	greater	proportion	of	
infants	in	the	term-	AGA	category	(the	lowest	mortality	risk)	and	lower	
proportions	in	the	high-	risk	categories	(term-	SGA-	LBW,	preterm-	AGA-	
LBW,	and	preterm-	SGA).	The	results	of	the	regression	analyses	reflected	
these	reductions,	but	were	not	statistically	significant	(Table	3).
Figure	1	displays	the	bimonthly	mean	birth	weight	in	the	placebo	
and	vaccinated	groups	versus	weekly	influenza	virus	circulation.	Figure	
S5	shows	the	same	graph	but	with	circulation	levels	stratified	by	the	
type	of	influenza	virus.	Generally,	there	were	patterns	of	increased	dif-
ferences	in	birth	weight,	comparing	vaccination	with	placebo,	at	times	
of	high	circulation	for	each	viral	strain.
With	regard	to	secular	trends,	the	mean	birth	weight	increased	by	
5	g	(95%	CI	2–8)	per	month	for	the	placebo	group	and	7	g	(95%	CI	4–10)	
per	month	for	the	vaccinated	group	through	the	course	of	the	study.
Table	S2	presents	the	effect	of	maternal	vaccination	on	birth	weight	
and	pregnancy	length,	stratified	by	calendar	time	of	vaccination	(divided	
into	4-	month	blocks	owing	to	the	sample	size).	Compared	with	women	in	
the	placebo	group,	birth	weight	was	significantly	higher	among	mothers	
vaccinated	during	January–April	2012	(mean	difference	109	g,	95%	CI	
27–191),	and	during	January–April	2013	(mean	difference	112	g,	95%	
CI	12–212).	A	statistically	significant	reduction	was	seen	for	those	vacci-
nated	during	September–December	2011	(mean	difference	−101	g,	95%	
CI	−185	to	−17).	Among	women	vaccinated	during	May–August	2011,	
statistically	significant	reductions	in	LBW	(RR	0.70,	95%	CI	0.55–0.89)	
and	SGA	(RR	0.81,	95%	CI	0.67–0.99)	were	seen.	Statistically	significant	
reductions	in	preterm	births	were	found	among	those	vaccinated	during	
May–August	2012	(RR	0.55,	95%	CI	0.33–0.92).
The	vaccination	effect	on	birth	weight	was	stratified	by	exposure	to	
high	levels	of	influenza	virus	circulation	in	the	third	trimester	(Table	4).	
Although	none	of	the	birth	weight	effects	remained	statistically	signifi-
cant,	the	data	were	indicative	of	a	dose-	response	pattern.	Namely,	the	
greater	the	proportion	of	the	third	trimester	exposed	to	high	influenza	
circulation,	 the	greater	 the	magnitude	of	birth	weight	gain	associated	
with	vaccination	(Table	4).	This	dose-	response	pattern	could	be	observed	
when	the	analysis	was	limited	to	women	who	were	vaccinated	before	
26	weeks,	but	the	effects	were	not	statistically	significant	(Table	4).
When	stratifying	by	timing	of	vaccination	in	pregnancy,	an	increase	
in	birth	weight	was	seen	 in	each	category,	but	was	only	statistically	
significant	among	women	vaccinated	before	26	weeks	(48	g,	95%	CI	
6–90)	(Table	4).
A	 dose-	response	 relationship	 between	 exposure	 to	 high	 influ-
enza	 circulation	 and	 pregnancy	 length	 was	 observed	 but	 was	 not	
TABLE  2 Birth	weight	distribution,	by	vaccine	typea	and	vaccination	status.
Birth weight
Vaccine 1 Vaccine 2 Combined
Placebo (n=993) Vaccine (n=1030) Placebo (n=368) Vaccine (n=350) Placebo (n=1361) Vaccine (n=1380)
Mean,	g 2749 2785 2796 2859 2762 2804
Median,	g 2760 2800 2790 2860 2770 2810
Interquartile	range,	g 2460–3040 2520–3080 2520–3075 2560–3150 2470–3050 2520–3100
Range,	g 820–4420 1260–4110 1360–4140 1590–4800 820–4420 1260–4800
Low	birth	weightb 278 (28.0) 239	(23.2) 87	(23.6) 76 (21.7) 365	(26.8) 315	(22.8)
aVaccine	types	are	described	in	Appendix	S1.
bValues	given	as	number	(percentage).
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statistically	 significant	 (Table	 S3).	However,	 a	 statistically	 significant	
increase	 in	 pregnancy	 length	was	 found	 among	mothers	who	were	
vaccinated	between	26	weeks	and	less	than	30	weeks,	when	at	least	
half	of	their	third	trimester	had	been	exposed	to	high	influenza	virus	
circulation.	When	 removing	 the	 circulation	 stratification,	 there	was	
a	 statistically	 significant	 positive	 effect	 on	 pregnancy	 length	 among	
those	vaccinated	between	26	weeks	and	less	than	30	weeks,	but	not	
for	those	vaccinated	before	or	after	that	time	(Table	S3).
When	the	proportion	of	a	pregnancy’s	third	trimester	exposed	to	
high	influenza	virus	circulation	was	examined	as	a	continuous	variable,	
vaccination	during	periods	of	greater	influenza	virus	circulation	had	a	
greater	positive	effect	on	birth	weight	than	vaccination	during	periods	
of	lower	influenza	virus	circulation,	but	the	effect	modification	was	not	
statistically	significant.	A	positive	trend	of	increased	pregnancy	length	
was	observed	among	vaccinated	individuals	with	greater	third	trimes-
ter	exposure	to	 influenza	circulation	than	with	 lower	 third	 trimester	
exposure;	however,	the	effect	modification	was	not	statistically	signif-
icant	(data	not	shown).
4  | DISCUSSION
Maternal	 influenza	 vaccination	 increased	 birth	 weight	 among	 live	
births	 in	 the	 present	 study.	 The	 magnitude	 differed	 by	 season,	
appearing	 greatest	 among	 pregnancies	 for	which	 the	 third	 trimes-
ter	occurred	at	a	time	of	high	 influenza	virus	circulation;	however,	
the	 results	were	 inconclusive.	 Sarlahi	District	 in	 southern	Nepal	 is	
a	subtropical	 region	that	experiences	 influenza	virus	circulation	for	
two-	thirds	of	the	year	and	is	epidemiologically	similar	to	other	parts	
of	South	Asia.	Seasonal	peaks	of	circulation	appear	to	overlap	tem-
porally	with	an	increased	effect	of	vaccination	on	birth	weight.	In	a	
low-	resource	setting	such	as	rural	Nepal,	vaccination	delivery	can	be	
logistically	difficult;	therefore,	alternatives	to	year-	round	vaccination	T
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F IGURE  1 Mean	birth	weight	in	relation	to	influenza	virus	
circulation.
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should	 be	 considered.	 The	 present	 study	 also	 indicated	 a	marginal	
reduction	in	the	prevalence	of	 infants	born	both	preterm	and	SGA.	
No	clear	 trends	were	observed	to	 link	timing	of	vaccination	during	
pregnancy	with	the	effects	on	birth	weight.
Previous	 observational	 studies	 reported	 mixed	 results	 regarding	
the	effect	of	maternal	 influenza	vaccination	on	birth	outcomes.	Data	
collected	 in	 the	USA	between	2004	 and	2009	 showed	no	 effect	 on	
preterm	birth	 or	 SGA,19	 although	 rates	 of	 these	 outcomes	 are	much	
lower	 in	 the	USA	than	 in	 low-	income	countries.	Data	 from	the	2009	
US	H1N1	 influenza	 pandemic	 showed	 that	 preterm	 rates	were	 37%	
lower	(adjusted	odds	ratio	0.63,	95%	CI	0.47–0.84)	for	the	vaccinated	
versus	the	non-	vaccinated,	but	there	was	a	minimal	birth	weight	effect	
and	no	change	in	SGA	or	LBW.20	Although	these	observational	studies	
adjusted	for	confounders,	residual	confounding	is	likely	because	vacci-
nated	women	likely	differ	in	characteristics	from	unvaccinated	women.
Four	maternal	influenza	vaccination	trials	have	been	conducted	to	
date,	including	the	Nepal	Mothers’	Gift	Trial.15,16	A	Bangladeshi	study	
found	 only	 a	 statistically	 significant	 increase	 in	 birth	 weight	 and	 a	
decrease	in	SGA	rate	during	the	high	influenza	virus	circulation	period.14 
Studies	conducted	in	South	Africa13	and	Mali12	found	no	effect	on	birth	
weight	or	LBW,	irrespective	of	influenza	virus	circulation.	The	consis-
tency	of	the	present	findings	with	the	Bangladeshi	study14 could imply 
a	regional	difference.	The	LBW	and	SGA	rates	are	substantially	higher	
in	Asia	than	in	Sub-	Saharan	Africa,21	which	might	indicate	varying	eti-
ological	 factors	 that	 affect	birth	weight.	An	outcome	of	 LBW,	which	
is	 comprised	of	preterm	delivery	and/or	 fetal	 growth	 restriction,	 can	
result	from	various	maternal	exposures,	including	nutrition,	substance	
misuse,	environment,	and	infection.21	Rates	of	malnutrition	are	high	in	
Asia;	therefore,	it	is	possible	that	poor	nutrition	aggravates	the	adverse	
effect	of	infectious	disease.	There	is	extensive	evidence	linking	malnu-
trition	with	increased	susceptibility	to,	and/or	severity	of,	infection.22 A 
study	conducted	in	the	Democratic	Republic	of	Congo23	showed	that	
the	association	between	malaria	and	fetal	growth	restriction	was	only	
present	 if	women	presented	with	poor	nutritional	 indicators,	such	as	
low	body	mass	index	and	low	mid-	upper	arm	circumference.	The	pres-
ent	study	did	not	capture	sufficient	cases	of	influenza	or	influenza-	like	
illness	to	stratify	the	analyses	by	maternal	nutrition	status.
The	present	study	examined	only	the	effect	of	vaccination	on	birth	
weight	and	pregnancy	length;	however,	there	is	evidence	to	suggest	that	
influenza	vaccination	might	positively	impact	fetal	and	neonatal	health	
outcomes	 through	 other	mechanisms.	Animal	 studies	 have	 indicated	
effects	of	maternal	 influenza	 infection	on	 fetal	 brain	development,24 
and	an	analysis	of	the	1918	influenza	pandemic	found	excess	risk	of	
cardiovascular	disease	among	individuals	born	during	this	pandemic.25 
The	present	study	found	a	substantial	reduction	in	preterm-	SGA	inci-
dence	among	vaccinated	mothers.	Preterm-	SGA	infants	experience	the	
highest	 risk	 of	 neonatal	 and	 postneonatal	mortality.	Asian	 data	 that	
were	comprised	predominantly	of	South	Asian	studies	showed	a	17-	
fold	increase	in	neonatal	mortality	risk	when	comparing	preterm-	SGA	
with	term-	AGA	infants.8	Rates	of	stillbirth	have	also	been	reported	to	
be	higher	among	growth-	restricted	and/or	preterm	fetuses.26	Although	
the	 present	 sample	 size	was	 not	 large	 enough	 to	 detect	 differences	
TABLE  4 The	effect	of	vaccination	on	birthweight	(in	g),	stratified	by	extent	of	third-	trimester	exposure	to	high	influenza	circulation	and	
timing	of	vaccination	in	pregnancy.
Vaccination
Combined Vaccinated at <26 wk Vaccinated at 26–<30 wk Vaccinated at ≥30 wk
n β (95% CI) n β (95% CI) n β (95% CI) n β (95% CI)
0%	to	<25%	of	third	trimester	 
in	high	circulation	period
Placebo 1142 Ref. 779 Ref. 225 Ref. 138 Ref.
Vaccinated 1130 38	(−6	to	81) 766 42	(−11	to	95) 203 30	(−68	to	128) 161 39	(−85	to	163)
25%	to	<50%	of	third	trimester	 
in	high	circulation	period
Placebo 367 Ref. 244 Ref. 94 Ref. 29 Ref.
Vaccinated 384 21	(−49	to	90) 245 51	(−37	to	138) 114 −80	(−205	to	44) 25 109	(−136	to	353)
50%	to	<75%	of	third	trimester	 
in	high	circulation	period
Placebo 240 Ref. 136 Ref. 67 Ref. 37 Ref.
Vaccinated 236 66	(−32	to	165) 136 64	(−59	to	186) 64 32	(−157	to	222) 36 124	(−175	to	423)
75%–100%	of	third	trimester	 
in	high	circulation	period
Placebo 90 Ref. 43 Ref. 29 Ref. 18 Ref.
Vaccinated 86 111	(−51	to	273) 47 118	(−119	to	354) 24 304	(−14	to	622) 25 −86	(−397	to	225)
Combined
Placebo 1845 Ref. 1206 Ref. 416 Ref. 223 Ref.
Vaccinated 1843 42	(8	to	76) 1191 48	(6	to	90) 405 23	(−47	to	93) 247 48	(−52	to	148)
Abbreviation:	CI,	confidence	interval.
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in	 neonatal	 mortality,	 a	 protective	 effect	 against	 mortality	might	 be	
expected	with	the	reduction	in	the	proportion	of	preterm-	SGA	infants.
The	present	study	could	not	determine	what	period	in	pregnancy	
would	be	associated	with	the	largest	effect	from	exposure	to	influenza	
virus.	Given	 that	 the	greatest	 fetal	weight	gain	occurs	 late	 in	preg-
nancy,27	the	present	study	focused	on	such	exposure	during	the	third	
trimester;	however,	exposure	at	an	earlier	stage	 in	pregnancy	could	
trigger	 inflammatory	 responses	 that	 affect	 other	 health	 outcomes.	
In	attempting	to	understand	 the	 interaction	between	seasonality	of	
influenza	virus	circulation	and	 the	stages	of	pregnancy,	 the	present	
study	could	not	definitively	identify	an	ideal	time	for	maternal	influ-
enza	vaccination.	Additionally,	the	viral	surveillance	performed	might	
have	 been	 limited	 because	 nasal	 swabs	 for	 influenza	 testing	 were	
taken	only	among	women	who	reported	a	febrile	respiratory	illness.
In	conclusion,	maternal	influenza	vaccination	exerted	the	greatest	
effect	on	birth	weight	among	pregnant	women	who	were	exposed	to	
high	 influenza	virus	circulation	during	the	third	trimester.	A	strategy	
of	seasonal	maternal	influenza	vaccination	in	resource-	limited	settings	
could	potentially	increase	birth	weight	during	periods	of	high	influenza	
circulation.	Taking	 into	 consideration	 the	barriers	 to	providing	year-	
round	vaccination,	it	may	be	possible	to	target	key	times	of	the	year	to	
maximize	the	impact	on	birth	outcomes.
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